As Walter Winchell used to say, “Good evening, Mr. and Mrs. America from border to border and coast to coast and all the ships at sea. Let’s go to press.” First up today is great news for diabetics who are priced out of using a Continuous Glucose Monitor (CGM) to aid in their control of diabetes – and by association implications for dialysis patients since so many are also diabetics.
Yesterday in the financial news I read that both Abbott and Dexcom stock took a rather big bump up after it was announced that Medicare will cover CGMs for a broader group of patients starting in April. The policy change includes broader language that appears to include people with non-insulin-treated diabetes and a history of hypoglycemic event(s) as well as who take daily insulin – not the previous requirement for multiple insulin shots. Since this is breaking news and I’m certain not yet been promulgated down the chain to prescribing physicians, it is still a breakthrough worthy of following up on. I certainly intend to as I am currently spending over $200 per month out of pocket for the Libre 3 CGM.
As previously mentioned, on March 1 2023 I visited Fresenius Granbury, TX for my monthly visit with my Team Nurse Cindy and labs. The results were indeed available the next day. Herein I present the results limited to those not meeting the established parameters. There are five in total given below. My short comments are at lab footers.
t
Leave a Reply